NCT01696383

Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia

Assessing the Efficacy of DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination), as a Replacement Therapy in Glaucoma Patients in Russia, Previously on Prior Prostaglandin Analogue or Beta-blocker Monotherapy

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5%) from prior prostaglandin analogue or beta-blocker monotherapy in Russian glaucoma patients with open-angle glaucoma or ocular hypertension whose intraocular pressure (IOP) is uncontrolled while on their current treatment.

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)	One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks

Timeline

• Start date: 2013-02-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2012-10-01
• Last updated: 2013-02-07